Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Shares Outstanding (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Shares Outstanding for 7 consecutive years, with $101.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 21.66% to $101.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $101.7 million through Dec 2025, up 21.66% year-over-year, with the annual reading at $101.7 million for FY2025, 21.66% up from the prior year.
  • Shares Outstanding for Q4 2025 was $101.7 million at Beam Therapeutics, roughly flat from $101.4 million in the prior quarter.
  • The five-year high for Shares Outstanding was $101.7 million in Q4 2025, with the low at $61.7 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $79.6 million, with a median of $78.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding soared 34.29% in 2021, then rose 2.45% in 2024.
  • Over 5 years, Shares Outstanding stood at $68.4 million in 2021, then increased by 4.22% to $71.3 million in 2022, then grew by 14.53% to $81.6 million in 2023, then rose by 2.45% to $83.6 million in 2024, then increased by 21.66% to $101.7 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $101.7 million, $101.4 million, and $100.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.